Synthesis and biological evaluation of novel phenothiazine derivatives as non-peptide arginine vasopressin V2 receptor antagonists

被引:0
|
作者
Shuang Zhi [1 ]
Shuai Mu [1 ,2 ]
Ying Liu [2 ]
Min Gong [2 ]
Ping-Bao Wang [2 ]
Deng-Ke Liu [2 ]
机构
[1] School of Chemical Engineering and Technology,Tianjin University
[2] Tianjin Institute of Pharmaceutical Research
关键词
Arginine vasopressin V2 receptor; antagonist; Phenothiazine derivatives; Synthesis; Biological activities;
D O I
暂无
中图分类号
O626 [杂环化合物];
学科分类号
摘要
A series of novel phenothiazine derivatives was synthesized and tested for arginine vasopressin receptor antagonist activity.They were synthesized as novel arginine vasopressin receptor antagonists from phenothiazine as a scaffold via successive acylation,reduction and acylation reactions.Their structures were characterized by ~1H NMR,C NMR and HRMS,and biological activity was evaluated by in vitro and in vivo studies.The in vitro binding assay indicated that several compounds are potent selective V2 receptor antagonists.Compounds with promising binding affinity to V2 receptors were selected to conduct the in vivo diuretic studies on Sprague-Dawley rats.Among them.In,1r,1t and 1v exhibited excellent diuretic activity,especially 1 rand 1 v.Therefore,1r and 1v are potent novel AVPV2 receptor antagonist candidates.
引用
收藏
页码:627 / 630
页数:4
相关论文
共 50 条
  • [1] Synthesis and biological evaluation of novel phenothiazine derivatives as non-peptide arginine vasopressin V2 receptor antagonists
    Zhi, Shuang
    Mu, Shuai
    Liu, Ying
    Gong, Min
    Wang, Ping-Bao
    Liu, Deng-Ke
    CHINESE CHEMICAL LETTERS, 2015, 26 (05) : 627 - 630
  • [2] Synthesis and biological evaluation of novel indoloazepine derivatives as non-peptide vasopressin V2 receptor antagonists
    Matthews, JM
    Greco, MN
    Hecker, LR
    Hoekstra, WJ
    Andrade-Gordon, P
    de Garavilla, L
    Demarest, KT
    Ericson, E
    Gunnet, JW
    Hageman, W
    Look, R
    Moore, JB
    Maryanoff, BE
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (04) : 753 - 756
  • [3] Synthesis and biological activity of novel 4,4-difluorobenzazepine derivatives as non-peptide antagonists of the arginine vasopressin V1A receptor
    Shimada, Y
    Taniguchi, N
    Matsuhisa, A
    Akane, H
    Kawano, N
    Suzuki, T
    Tobe, T
    Kakefuda, A
    Yatsu, T
    Tahara, A
    Tomura, Y
    Kusayama, T
    Wada, K
    Tsukada, J
    Orita, M
    Tsunoda, T
    Tanaka, A
    BIOORGANIC & MEDICINAL CHEMISTRY, 2006, 14 (06) : 1827 - 1837
  • [4] Synthesis and Biological Evaluation of Substituted Desloratadines as Potent Arginine Vasopressin V2 Receptor Antagonists
    Mu, Shuai
    Liu, Ying
    Gong, Min
    Liu, Deng-Ke
    Liu, Chang-Xiao
    MOLECULES, 2014, 19 (02) : 2694 - 2706
  • [5] Recent discovery and development of non-peptide vasopressin V2 receptor agonists
    Kondo, K
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2002, 12 (08) : 1249 - 1258
  • [6] Non-peptide arginine-vasopressin antagonists: the vaptans
    Decaux, Guy
    Soupart, Alain
    Vassart, Gilbert
    LANCET, 2008, 371 (9624): : 1624 - 1632
  • [7] Identification of novel selective V2 receptor non-peptide agonists
    Del Tredici, Andria L.
    Vanover, Kim E.
    Knapp, Anne E.
    Bertozzi, Sine M.
    Nash, Norman R.
    Burstein, Ethan S.
    Lameh, Jelveh
    Currier, Erika A.
    Davis, Robert E.
    Brann, Mark R.
    Mohell, Nina
    Olsson, Roger
    Piu, Fabrice
    BIOCHEMICAL PHARMACOLOGY, 2008, 76 (09) : 1134 - 1141
  • [8] Vasopressin V2 receptor antagonists
    Wong, LL
    Verbalis, JG
    CARDIOVASCULAR RESEARCH, 2001, 51 (03) : 391 - 402
  • [9] Vasopressin V2 receptor antagonists
    Verbalis, JG
    JOURNAL OF MOLECULAR ENDOCRINOLOGY, 2002, 29 (01) : 1 - 9
  • [10] Lixivaptan, a non-peptide vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia
    Ghali, Jalal K.
    Zmily, Hammam D.
    Farah, Jareer O.
    Daifallah, Suleiman
    IDRUGS, 2010, 13 (11) : 782 - 792